616 - AMG 714 (Anti-IL-15 MAB) Halts the Progression of Aberrant Intraepithelial Lymphocytes in Refractory Celiac Disease type II (RCD-II): A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study Evaluating AMG 714 in Adult Patients with RCD-II/Pre-EATL

2018 ◽  
Vol 154 (6) ◽  
pp. S-129-S-130 ◽  
Author(s):  
Christophe Cellier ◽  
Gerd Bouma ◽  
Tom van Gils ◽  
Sherine Khater ◽  
Georgia Malamut ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Intraepithelial Lymphocytes ◽  
Disease Type ◽  
Adult Patients ◽  
Controlled Study ◽  
Type Ii ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Refractory Celiac Disease

The Intracellular Intensity of CD3 on Aberrant Intraepithelial Lymphocytes Is a Prognostic Factor of the Progression to Overt Lymphoma in Refractory Celiac Disease Type II (Pre-Enteropathy-Associated T Cell Lymphoma)

2020 ◽  
Vol 38 (6) ◽  
pp. 490-499 ◽  
Author(s):  
Carlota García-Hoz ◽  
Laura Crespo ◽  
Natalia Lopez ◽  
Ana De Andrés ◽  
Raquel Ríos León ◽  
...  
Keyword(s):  
Celiac Disease ◽  
T Cell ◽  
Cell Lymphoma ◽  
Intraepithelial Lymphocytes ◽  
Disease Type ◽  
T Cell Lymphoma ◽  
Control Group ◽  
Type Ii ◽  
Refractory Celiac Disease ◽  
Single Center Study

<b><i>Background:</i></b> Refractory celiac disease type II (RCD-II) is a very rare yet severe complication of celiac disease (CD) with a 50% rate of progression to Enteropathy-associated T-cell lymphoma (EATL). Timely diagnosis and treatment of RCD-II is of the essence and requires the identification of a population of frequently clonal, phenotypically aberrant intraepithelial lymphocytes (IELs). Flow Cytometry of intestinal IELs is the recommended method to identify the aberrant surface CD3-negative (sCD3<sup>–</sup>) intracytoplasmic CD3-positive (icCD3ε<sup>+</sup>) IELs, and a proportion of &#x3e;20% is diagnostic of RCD-II. There is substantial heterogeneity in the clinical course of RCD-II, and insufficient information on prognostic factors. <b><i>Aim:</i></b> To establish flow cytometric predictors of the clinical evolution of RCD-II, to help guide treatment approaches. <b><i>Patients and Methods:</i></b> Retrospective single-center study of clinical and immunological features of 6 RCD-II patients and a control group, both identified from a 2,000-patient cohort over 16 years. IEL subset frequencies and the intensity of staining for surface (s) and intracytoplasmic (ic) CD3ε+ on IEL subsets were quantified and correlated with the clinical outcome. <b><i>Results:</i></b> Unexpectedly, the frequency of aberrant sCD3<sup>–</sup> icCD3ε<sup>+</sup> cells at diagnosis did not correlate with histological or clinical affection. However, a higher intensity of icCD3ε<sup>+</sup> staining in the aberrant IELs relative to expression on normal IELs correlated with monoclonality and with worse clinical outcomes. <b><i>Conclusion:</i></b> The ratio of icCD3ε<sup>+</sup> on aberrant IELs vs. normal IELs appears to be a useful indicator of prognosis at the time of diagnosis, and may represent a novel tool in the follow-up of RCD-II patients after therapy.

Serendipity in Refractory Celiac Disease: Full Recovery of Duodenal Villi and Clinical Symptoms after Fecal Microbiota Transfer

2016 ◽  
Vol 25 (3) ◽  
pp. 385-388 ◽  
Author(s):  
Yvette H. Van Beurden ◽  
Tom Van Gils ◽  
Nienke A. Van Gils ◽  
Zain Kassam ◽  
Chris J.J. Mulder ◽  
...  
Keyword(s):  
Celiac Disease ◽  
T Cell ◽  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Cell Lymphoma ◽  
Fecal Microbiota ◽  
Disease Type ◽  
T Cell Lymphoma ◽  
Type Ii ◽  
Refractory Celiac Disease

Treatment of refractory celiac disease type II (RCD II) and preventing the development of an enteropathy associated T-cell lymphoma in these patients is still difficult. In this case report, we describe a patient with RCD II who received fecal microbiota transfer as treatment for a recurrent Clostridium difficile infection, and remarkably showed a full recovery of duodenal villi and disappearance of celiac symptoms. This case suggests that altering the gut microbiota may hold promise in improving the clinical and histological consequences of celiac disease and/or RCD II. Abbreviations: CDI: Clostridium difficile infection; EATL : enteropathy associated T-cell lymphoma; FMT: fecal microbiota transfer; IEL: intraepithelial lymphocytes; RCD II: refractory celiac disease type II; TPN: total parenteral nutrition.

A randomized, double-blind, placebo-controlled study of the efficacy and tolerability of policosanol in adolescents with type II hypercholesterolemia

2002 ◽  
Vol 63 (4) ◽  
pp. 286-303 ◽  
Author(s):  
Gladys Castaño ◽  
Rosa Más ◽  
Lilia Fernández ◽  
José Illnait ◽  
Eric Hernández ◽  
...  
Keyword(s):  
Controlled Study ◽  
Type Ii ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals A242 SIGMOID PERFORATION: A RARE CASE OF REFRACTORY CELIAC DISEASE TYPE II

2018 ◽  
Vol 1 (suppl_2) ◽  
pp. 354-354
Author(s):  
R Chibbar ◽  
J Nostedt ◽  
D Mihalicz ◽  
R Mclean ◽  
J deschenes ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Rare Case ◽  
Disease Type ◽  
Type Ii ◽  
Refractory Celiac Disease ◽  
Sigmoid Perforation

scholarly journals A Randomized, Double Blind, Placebo-Controlled Study of MAP0004 in Adult Patients With Migraine

2009 ◽  
Vol 49 (6) ◽  
pp. 826-837 ◽  
Author(s):  
Sheena K. Aurora ◽  
Todd D. Rozen ◽  
Shashidhar H. Kori ◽  
Stephen B. Shrewsbury
Keyword(s):  
Adult Patients ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Undenatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers

2013 ◽  
Vol 10 (1) ◽  
pp. 48 ◽  
Author(s):  
James P Lugo ◽  
Zainulabedin M Saiyed ◽  
Francis C Lau ◽  
Jhanna Pamela L Molina ◽  
Michael N Pakdaman ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Type Ii Collagen ◽  
Controlled Study ◽  
Type Ii ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Undenatured Type Ii Collagen

scholarly journals Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy

2010 ◽  
Vol 46 (6) ◽  
pp. 840-846 ◽  
Author(s):  
G J Tack ◽  
M J Wondergem ◽  
A Al-Toma ◽  
W H M Verbeek ◽  
A Schmittel ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Disease Type ◽  
Type Ii ◽  
Refractory Celiac Disease
Sign in / Sign up

Export Citation Format

Share Document